3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer

Bang, Y.; Kang, Y.; Kang, Woodae; Boku, Narikazu; Chung, Ho Young; Tursi, Jennifer; Lechuga, Maria; Verkh, Lev; Chao, Richard C.; Sobrero, Alberto

doi:10.1016/s1359-6349(07)71045-5

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunitinib has also been under investigation in gastric cancer, and in the interim report of the Phase II trial with sunitinib as single agent conducted in patients with gastric cancer treated after standard therapy, PR was noted in 2 of 72 patients and SD in 17 patients, PFS was 11.1 weeks and OS was 47.7 weeks (59). A Phase I/II study combining chemotherapy with sunitinib in this indication is ongoing.…”

Section: Vegfr Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers

Iwasaki¹,

Nihira²

2009

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Gastrointestinal tract cancers constitute a group of highest morbidity both in and outside Japan, and the prognosis still remains unfavorable when the disease has progressed to the unresectable stage. Since the late 1990s, a novel category of anti-cancer drugs, 'molecular-targeted drugs', has become available, and angiogenesis has been considered as one of the most important molecular targets for antitumor therapy since it is essential for tumor growth. Anti-angiogenic therapy inhibits tumor angiogenesis and promotes apoptosis of existing tumor blood vessels, thereby intercepting the supply of oxygen and nutrition essential for tumor growth and metastasis. It was also suggested that anti-angiogenic therapy effectively normalizes abnormal vascular permeability, and thereby decreases the interstitial pressure, which may improve delivery of concomitantly used chemotherapeutic agents to tumor cells. Vascular endothelial growth factor (VEGF) acts as one of the most potent stimulating agents of angiogenesis, and several strategies targeting the VEGF signaling pathway have been developed, including anti-VEGF antibodies, soluble receptors binding directly to VEGF ligand, anti-VEGF receptor (VEGFR) antibodies and VEGFR tyrosine kinase inhibitors. The breakthrough in the clinical development of anti-angiogenic therapy against colorectal cancer came in 2003 with a large prospective, randomized clinical trial of bevacizumab, a monoclonal antibody directed against VEGF. Anti-angiogenic therapy has introduced a highly effective, completely new mode of action in this area and is the new standard of care in advanced colorectal cancer, while still being tested in gastric cancer due to its convincing clinical benefit and its tolerability and combinability with multiple chemotherapeutic agents.

show abstract

Section: Vegfr Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers

Iwasaki¹,

Nihira²

2009

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…However, second-line treatments are clearly effective to some degree, with response rates in the region of 11%-32%, median TTP of 2.5-4.5 months, and median overall survival times of 5.4 -9.3 months achieved in these early analyses. It may be that, in the future, the introduction of molecularly targeted agents will further improve outcomes in this setting [52,68]. This potential is perhaps best illustrated by preliminary results from the phase II study of the oral, multitargeted TKI sunitinib in 42 evaluable gastric cancer patients with stage IV disease who had failed first-line chemotherapy.…”

Section: Is Second-line Cytotoxic Treatment In Gastric Cancer Likely mentioning

confidence: 99%

“…Single-agent sunitinib treatment was generally well tolerated, and the median PFS and overall survival times were reported to be 2.8 and 11.7 months, respectively. Recruitment of a second cohort of patients is ongoing, and studies of sunitinib in combination with chemotherapy are planned [68].…”

Section: Is Second-line Cytotoxic Treatment In Gastric Cancer Likely mentioning

confidence: 99%

Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents?

Pozzo

Barone

2008

The Oncologist

View full text Add to dashboard Cite

Globally, gastric cancer is the second most common cause of cancer-related death. The majority of gastric cancer patients will have at presentation or will ultimately develop overt metastatic disease. Meta-analysis has demonstrated not only that systemic chemotherapy can improve survival in patients with advanced disease but also that the best survival results in earlier randomized studies have been achieved with three-drug regimens containing a fluoropyrimidine, an anthracycline, and cisplatin. Although there has been little progress historically in improving median overall survival times beyond the 9-month plateau achievable with the standard epirubicin–cisplatin–infusional 5-fluoropyrimidine (ECF) combination, the availability of newer cytotoxic anticancer agents has provided some measure of optimism that current outcomes can be improved. A number of new triplet and doublet combinations incorporating docetaxel, oxaliplatin, irinotecan, capecitabine, and S-1 have been explored in randomized trials. Although some combinations, such as epirubicin–oxaliplatin–capecitabine, have been shown to be as effective as (or perhaps more effective than) ECF, and although promising early data have been derived for S-1 in combination with cisplatin, a lack of studies in which direct comparisons have been made currently hinders the identification of the optimal regimen in this setting. One factor that might contribute to the lack of clear progress is the absence of consensus on the utility of second-line cytotoxic treatments. It can therefore be concluded that, although there is no first-line regimen that is clearly the most appropriate platform for the investigation of biological agents, there are a number of combinations that have been shown to be effective and therefore good candidates.

show abstract

3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer

Cited by 2 publications

References 0 publications

Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers

Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers

Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents?

Contact Info

Product

Resources

About